Early use of vitamin B3 derivative may halve recurrence after first skin cancer.
“The authors found no convincing evidence that nicotinamide increased cancer risk, which helps address prior theoretical concerns. Although the study used a large clinical dataset and careful matching, it was observational, not a randomized trial.”